QCM
CRL icon

Qsemble Capital Management’s Charles River Laboratories CRL Stock Holding History

Qsemble Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,645
Closed -$456K – 420
2026
Q1 		$456K Sell
2,645
-701
-21% -$130K 0.03% 365
2025
Q4 		$667K Buy
+3,346
New +$607K 0.06% 337
2024
Q3 		– Sell
-1,187
Closed -$245K – 412
2024
Q2 		$245K Sell
1,187
-2,485
-68% -$563K 0.05% 374
2024
Q1 		$995K Buy
+3,672
New +$877K 0.22% 180

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Qsemble Capital Management's CRL Position: Q2 2026 in Review

Qsemble Capital Management sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 2,645 shares — an estimated $456K sold.

Qsemble Capital Management first reported a position in CRL in Q1 2024 and held it in 4 quarters. The position peaked at $995K in Q1 2024. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Qsemble Capital Management reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
  • Qsemble Capital Management sold 2,645 Charles River Laboratories shares in Q2 2026, an estimated $456K.
  • Qsemble Capital Management first reported a position in Charles River Laboratories in Q1 2024 and held it in 4 quarters.
  • Qsemble Capital Management's Charles River Laboratories position peaked at $995K in Q1 2024.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Qsemble Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.